EXTX Stock Overview
A clinical stage biopharmaceutical company, develops a technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy (ACT).
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
EXACT Therapeutics AS Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 5.75 |
| 52 Week High | NOK 15.00 |
| 52 Week Low | NOK 4.80 |
| Beta | 0.11 |
| 11 Month Change | 10.58% |
| 3 Month Change | -27.67% |
| 1 Year Change | -61.67% |
| 33 Year Change | -68.06% |
| 5 Year Change | n/a |
| Change since IPO | -81.93% |
Recent News & Updates
Here's Why We're Watching EXACT Therapeutics' (OB:EXTX) Cash Burn Situation
Aug 09
Is EXACT Therapeutics (OB:EXTX) In A Good Position To Invest In Growth?
Apr 20Recent updates
Here's Why We're Watching EXACT Therapeutics' (OB:EXTX) Cash Burn Situation
Aug 09Is EXACT Therapeutics (OB:EXTX) In A Good Position To Invest In Growth?
Apr 20We Think EXACT Therapeutics (OB:EXTX) Can Afford To Drive Business Growth
Sep 07We're Hopeful That EXACT Therapeutics (OB:EXTX) Will Use Its Cash Wisely
May 06Here's Why We're Watching EXACT Therapeutics' (OB:EXTX) Cash Burn Situation
Dec 30Companies Like EXACT Therapeutics (OB:EXTX) Are In A Position To Invest In Growth
Sep 15EXACT Therapeutics (OB:EXTX) Is In A Good Position To Deliver On Growth Plans
Jan 31We Think EXACT Therapeutics (OB:EXTX) Can Afford To Drive Business Growth
Aug 21We're Not Very Worried About EXACT Therapeutics' (OB:EXTX) Cash Burn Rate
May 21Shareholder Returns
| EXTX | NO Biotechs | NO Market | |
|---|---|---|---|
| 7D | 0% | -6.8% | -0.3% |
| 1Y | -61.7% | -59.1% | 1.2% |
Return vs Industry: EXTX underperformed the Norwegian Biotechs industry which returned -59.1% over the past year.
Return vs Market: EXTX underperformed the Norwegian Market which returned 1.2% over the past year.
Price Volatility
| EXTX volatility | |
|---|---|
| EXTX Average Weekly Movement | 10.7% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in NO Market | 10.4% |
| 10% least volatile stocks in NO Market | 2.7% |
Stable Share Price: EXTX's share price has been volatile over the past 3 months compared to the Norwegian market.
Volatility Over Time: EXTX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Norwegian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 12 | Per Walday | exact-tx.com |
EXACT Therapeutics AS, a clinical stage biopharmaceutical company, develops a technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy (ACT). The ACT is an approach to ultrasound-mediated, targeted drug enhancement with the potential to amplify the clinical utility of a range of therapeutic agents across various indications, including within oncology and brain diseases. The company’s ACT platform is under Phase I clinical trial for treatment of liver metastases; and pre-clinical studies for pancreatic, glioblastoma, and immunotherapy diseases, as well as CNS diseases and gene therapy.
EXACT Therapeutics AS Fundamentals Summary
| EXTX fundamental statistics | |
|---|---|
| Market cap | NOK 184.46m |
| Earnings (TTM) | -NOK 54.84m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.4x
P/E RatioIs EXTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EXTX income statement (TTM) | |
|---|---|
| Revenue | NOK 0 |
| Cost of Revenue | NOK 0 |
| Gross Profit | NOK 0 |
| Other Expenses | NOK 54.84m |
| Earnings | -NOK 54.84m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.71 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did EXTX perform over the long term?
See historical performance and comparison